William Blair equity research analyst Myles Minter’s note on the implications of the FDA approval of an updated COVID-19 vaccine from Moderna and Pfizer/BioNTech was cited by sector publication Pharmaceutical Technology.
“We see today’s outcome as the FDA maintaining autonomy and data-driven science decisions on vaccine approvability, important for industry integrity as a whole, regardless of any negative political sentiment,” Minter wrote in a note to investors that was cited by the publication.